Mayo Clinic developed an AI that analyzes routine pathology slides to classify meningiomas and predict recurrence risk, reducing dependency on advanced genetic testing.
Key Details
- 1Study published in The Lancet Digital Health by Mayo Clinic researchers.
- 2AI models analyze standard H&E slides to classify meningiomas and predict recurrence.
- 3Approach relies on images already used in clinical care, not on expensive genetic tests.
- 4Dataset included tissue samples, images, and clinical data from 672 patients.
- 5AI predictions remained valuable beyond traditional clinical factors like tumor grade or patient age.
- 6Further prospective studies are needed before routine clinical adoption.
Why It Matters
This work shows how imaging AI can extend the power of pathology slides, making advanced tumor insights more universally accessible even where genetic testing isn't available. It holds promise for improved, personalized cancer care using existing imaging workflows.
Source
EurekAlert
Related News
•EurekAlert
Broadband Optical Spectroscopy Enables Early NEC Detection in Preemies
Researchers successfully used a noninvasive broadband optical spectroscopy (BOS) device to detect necrotizing enterocolitis (NEC) early in premature infants.
•EurekAlert
UNM Researchers Use AI to Uncover Hidden Self-Harm Records in VA Data
Researchers develop a machine learning method to reveal self-harm history hidden in veterans' electronic medical records.
•EurekAlert
AI Tool Predicts Financial Toxicity Risk in Cancer Patients
Researchers developed a machine learning model to proactively identify cancer patients at high risk of financial stress from treatment.